1 EXHIBIT 10.6Consulting Agreement • February 8th, 2000 • Genelink Inc • Services-medical laboratories • New Jersey
1 EXHIBIT 10.7Consulting Agreement • January 28th, 2000 • Genelink Inc • Services-medical laboratories
EXHIBIT 10.11Employment Agreement • March 28th, 2003 • Genelink Inc • Services-medical laboratories • Pennsylvania
1 EXHIBIT 10.5 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT dated as of the 31st day of December, 1998 by and between GENELINK, INC., a Pennsylvania corporation (the "Company"), and JOHN R. DEPHILLIPO ("Executive").Employment Agreement • February 8th, 2000 • Genelink Inc • Services-medical laboratories
2 3 IN WITNESS WHEREOF, the parties have executed this Amendment to Consulting Agreement as of the date set forth above.Consulting Agreement • February 8th, 2000 • Genelink Inc • Services-medical laboratories
1 EXHIBIT 10.4Employment Agreement • February 8th, 2000 • Genelink Inc • Services-medical laboratories • New Jersey
1 EXHIBIT 10.4Employment Agreement • January 28th, 2000 • Genelink Inc • Services-medical laboratories • New Jersey
1 2 consultant, or in any other capacity or manner whatsoever, in any enterprise which shall so engage, but only to the extent that UNTHSC's purpose of such interest is to provide long-term DNA specimen preservation services which is in competition...Dna Specimen Repository Agreement • February 8th, 2000 • Genelink Inc • Services-medical laboratories • Texas
This agreement is made and entered into as of the 1st day of July, 1996, by and between GeneLink, Inc., a Corporation of the Common wealth of Pennsylvania, having a place of business at Margate, New Jersey (hereinafter "Genelink"); and university of...Collateral License Agreement • February 8th, 2000 • Genelink Inc • Services-medical laboratories
1 Exhibit 10.9 January 20, 2000 Jon C. Thomas Thomas Pierce & Company 3512 Maclay Boulevard., South Tallahassee, FL 32312 Re: Amendment #1 to Exclusive Sales and Marketing Distributorship Agreement dated January 5, 2000 Dear Jon: We hereby extend the...Exclusive Sales and Marketing Distributorship Agreement • February 8th, 2000 • Genelink Inc • Services-medical laboratories
STOCK PURCHASE AGREEMENTStock Purchase Agreement • October 17th, 2011 • Genelink Inc • Services-medical laboratories • New York
This Stock Purchase Agreement (this “Agreement”) is made as of October 13, 2011 (the “Signing Date”), by and among Capsalus Corp., a Nevada corporation (the “Purchaser”) and GeneLink, Inc., a Pennsylvania corporation (the “Seller”).
RECITALS:Bridge Loan Security Agreement • May 11th, 2006 • Genelink Inc • Services-medical laboratories • New York
1 EXHIBIT 10.8 January 5, 2000Exclusive Sales & Marketing Distributorship Agreement • February 8th, 2000 • Genelink Inc • Services-medical laboratories
LICENSE AND DISTRIBUTION AGREEMENTLicense and Distribution Agreement • October 17th, 2011 • Genelink Inc • Services-medical laboratories • New York
THIS LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”) dated the 13th day of October, 2011 (“Effective Date”), is by and between GENELINK, INC., a Pennsylvania corporation (“GeneLink”), with a principal business address at 317 Wekiva Springs Road, Suite 200, Longwood, FL 32779 and Gene Elite LLC, a Delaware limited liability company (“Licensee”), with a principal business address at 1481 North Ocean Boulevard, Pompano Beach, FL 33062.
GENELINK BIOSCIENCES AGREES TO SELL GENEWIZE LIFE SCIENCESStock Purchase Agreement • October 17th, 2011 • Genelink Inc • Services-medical laboratories
ORLANDO, FL – Oct. 13, 2011 – GeneLink Biosciences, Inc. (OTCBB:GNLK), a leading consumer genomics biotech company, has finalized a definitive agreement with Capsalus Corp. (OTCBB:WELL), a public company operating in the health and wellness space, to sell the stock of its wholly owned direct-selling subsidiary GeneWize Life Sciences, Inc., pending GeneLink shareholder approval and other related terms. The deal enables GeneLink to leverage the strengths of its sales and marketing partners to accelerate its growth strategy and to focus on the company’s core competencies.
Accounting for Sale of GeneWize and the Licensing and Distribution Agreement and Related WarrantsStock Purchase Agreement • March 20th, 2012 • Genelink Inc • Services-medical laboratories
In October 2011, GeneLink, Inc. (“the Company”, “GeneLink” or “the Seller”) entered into certain agreements for the sale of its wholly owned subsidiary, GeneWize Life Sciences, Inc. (“GeneWize”) to Capsalus Corp. (“Capsalus” or “the Purchaser”). The transaction involves i) a Stock Purchase Agreement (for the sale of the sub that includes earnout consideration), and an ii) an Interim Management agreement where the Purchaser will receive all profit earned by the GeneWize from October 1, 2011 through the closing of the sale (which is not yet complete and pending shareholder approval at a special meeting).
WARRANT PURCHASE AGREEMENTWarrant Purchase Agreement • October 17th, 2011 • Genelink Inc • Services-medical laboratories • Pennsylvania
This WARRANT PURCHASE AGREEMENT (this “Agreement”) dated the 13th day of October, 2011 by and between GeneLink, Inc., a Pennsylvania corporation (“GeneLink”), with its principal business address at 317 Wekiva Springs Road, Suite 200, Longwood, FL 32779 and Gene Elite LLC, a Delaware limited liability company (“Gene Elite”), with a principal business address at 1481 North Ocean Boulevard, Pompano Beach, FL 33082.
ITEM 10.3Convertible Loan Security Agreement • June 14th, 2006 • Genelink Inc • Services-medical laboratories • New York
ITEM 10.1Convertible Secured Loan Agreement • June 14th, 2006 • Genelink Inc • Services-medical laboratories • New York
INTERIM MANAGEMENT AGREEMENTInterim Management Agreement • October 17th, 2011 • Genelink Inc • Services-medical laboratories • New York
THIS AGREEMENT (“Agreement”) is entered into this 13th day of October, 2011, effective as of October 1, 2011 by and among CAPSALUS CORP., a Nevada corporation with its principal place of business at 2675 Paces Ferry Road, Atlanta, GA 30339 (“Purchaser”), GENELINK, INC., a Pennsylvania corporation with its principal place of business at 317 Wekiva Springs Road, Suite 200, Longwood, FL 32779 (“GeneLink”) and GENEWIZE LIFE SCIENCES, INC., a Delaware corporation with its principal place of business at 317 Wekiva Springs Road, Suite 200, Longwood, FL 32779 (the “Company”) (Purchaser, GeneLink, and the Company are hereinafter collectively referred to as the “Parties”). All capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Stock Purchase Agreement (as hereinafter defined).
